154 related articles for article (PubMed ID: 36494095)
1. A Genetic Assessment of Dopamine Agonist-Induced Impulse Control Disorder in Patients With Prolactinoma.
Sahin S; Sudutan T; Kavla Y; Durcan E; Özogul YY; Poyraz BC; Sayitoglu M; Ozkaya HM; Kadioglu P
J Clin Endocrinol Metab; 2023 May; 108(6):e275-e282. PubMed ID: 36494095
[TBL] [Abstract][Full Text] [Related]
2. Dopamine Agonist-Induced Impulse Control Disorders in Patients With Prolactinoma: A Cross-Sectional Multicenter Study.
Dogansen SC; Cikrikcili U; Oruk G; Kutbay NO; Tanrikulu S; Hekimsoy Z; Hadzalic A; Gorar S; Omma T; Mert M; Akbaba G; Yalin GY; Bayram F; Ozkan M; Yarman S
J Clin Endocrinol Metab; 2019 Jul; 104(7):2527-2534. PubMed ID: 30848825
[TBL] [Abstract][Full Text] [Related]
3. Dopamine agonist-induced impulse control disorders in a patient with prolactinoma.
Almanzar S; Zapata-Vega MI; Raya JA
Psychosomatics; 2013; 54(4):387-91. PubMed ID: 23261076
[No Abstract] [Full Text] [Related]
4. DRD and GRIN2B polymorphisms and their association with the development of impulse control behaviour among Malaysian Parkinson's disease patients.
Zainal Abidin S; Tan EL; Chan SC; Jaafar A; Lee AX; Abd Hamid MH; Abdul Murad NA; Pakarul Razy NF; Azmin S; Ahmad Annuar A; Lim SY; Cheah PS; Ling KH; Mohamed Ibrahim N
BMC Neurol; 2015 Apr; 15():59. PubMed ID: 25896831
[TBL] [Abstract][Full Text] [Related]
5. Impulse control disorders in patients with dopamine agonist-treated pituitary adenomas: a cross-sectional multicenter study.
Almalki MH; Alsuraikh MA; Almalki E; Aziz F; Almazrouei R; AlDahmani KM; Alshahrani F; Alaqeel M; Mahzari M; Ekhzaimy A
Pituitary; 2024 Apr; 27(2):197-203. PubMed ID: 38345719
[TBL] [Abstract][Full Text] [Related]
6. Clinical-genetic model predicts incident impulse control disorders in Parkinson's disease.
Kraemmer J; Smith K; Weintraub D; Guillemot V; Nalls MA; Cormier-Dequaire F; Moszer I; Brice A; Singleton AB; Corvol JC
J Neurol Neurosurg Psychiatry; 2016 Oct; 87(10):1106-11. PubMed ID: 27076492
[TBL] [Abstract][Full Text] [Related]
7. Impulse Control Disorders in Patients with Pituitary Tumors Treated with Dopamine Agonists: A Systematic Review.
Hamblin R; Karavitaki N
Arch Med Res; 2023 Dec; 54(8):102910. PubMed ID: 37985276
[TBL] [Abstract][Full Text] [Related]
8. Dopamine D3 receptor Ser9Gly variant is associated with impulse control disorders in Parkinson's disease patients.
Krishnamoorthy S; Rajan R; Banerjee M; Kumar H; Sarma G; Krishnan S; Sarma S; Kishore A
Parkinsonism Relat Disord; 2016 Sep; 30():13-7. PubMed ID: 27325396
[TBL] [Abstract][Full Text] [Related]
9. Patients with acromegaly might not be at higher risk for dopamine agonist-induced impulse control disorders than those with prolactinomas.
Ozkaya HM; Sahin S; Korkmaz OP; Durcan E; Sahin HR; Celik E; Poyraz BC; Kadioglu P
Growth Horm IGF Res; 2020 Dec; 55():101356. PubMed ID: 33010581
[TBL] [Abstract][Full Text] [Related]
10. Impulse control disorders in patients with prolactinoma receiving dopamine agonist therapy: a prospective study with 1 year follow-up.
Celik E; Ozkaya HM; Poyraz BC; Saglam T; Kadioglu P
Endocrine; 2018 Dec; 62(3):692-700. PubMed ID: 30206771
[TBL] [Abstract][Full Text] [Related]
11. Treating prolactinomas with dopamine agonists: always worth the gamble?
Noronha S; Stokes V; Karavitaki N; Grossman A
Endocrine; 2016 Feb; 51(2):205-10. PubMed ID: 26336835
[TBL] [Abstract][Full Text] [Related]
12. Depression and Impulsivity Self-Assessment Tools to Identify Dopamine Agonist Side Effects in Patients With Pituitary Adenomas.
Hinojosa-Amaya JM; Johnson N; González-Torres C; Varlamov EV; Yedinak CG; McCartney S; Fleseriu M
Front Endocrinol (Lausanne); 2020; 11():579606. PubMed ID: 33193096
[No Abstract] [Full Text] [Related]
13. Cabergoline-related impulse control disorder in an adolescent with a giant prolactinoma.
Bulwer C; Conn R; Shankar A; Ferrau F; Kapur S; Ederies A; Korbonits M; Spoudeas HA
Clin Endocrinol (Oxf); 2017 Jun; 86(6):862-864. PubMed ID: 28346715
[No Abstract] [Full Text] [Related]
14. Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study.
Bancos I; Nannenga MR; Bostwick JM; Silber MH; Erickson D; Nippoldt TB
Clin Endocrinol (Oxf); 2014 Jun; 80(6):863-8. PubMed ID: 24274365
[TBL] [Abstract][Full Text] [Related]
15. The side effects of dopamine receptor agonist drugs in Chinese prolactinoma patients: a cross sectional study.
Ke X; Wang L; Chen M; Liu S; Yu N; Duan L; Gong F; Zhu H
BMC Endocr Disord; 2022 Apr; 22(1):97. PubMed ID: 35410236
[TBL] [Abstract][Full Text] [Related]
16. Increased prevalence of impulse control disorder symptoms in endocrine diseases treated with dopamine agonists: a cross-sectional study.
Beccuti G; Guaraldi F; Natta G; Cambria V; Prencipe N; Cicolin A; Montanaro E; Lopiano L; Ghigo E; Zibetti M; Grottoli S
J Endocrinol Invest; 2021 Aug; 44(8):1699-1706. PubMed ID: 33314003
[TBL] [Abstract][Full Text] [Related]
17. Status epilepticus induced by treatment with dopamine agonist therapy for giant prolactinoma: a case report.
Koguchi M; Nakahara Y; Ebashi R; Ogata A; Shimokawa S; Masuoka J; Abe T
J Med Case Rep; 2019 Jan; 13(1):18. PubMed ID: 30660191
[TBL] [Abstract][Full Text] [Related]
18. Impulse control disorders in hyperprolactinemic patients on dopamine agonist therapy.
Hamidianjahromi A; Tritos NA
Rev Endocr Metab Disord; 2022 Oct; 23(5):1089-1099. PubMed ID: 36125673
[TBL] [Abstract][Full Text] [Related]
19. Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists.
De Sousa SM; Chapman IM; Falhammar H; Torpy DJ
Endocrine; 2017 Feb; 55(2):618-624. PubMed ID: 27601019
[TBL] [Abstract][Full Text] [Related]
20. Genetics of impulse control disorders in Parkinson's disease.
Cormier F; Muellner J; Corvol JC
J Neural Transm (Vienna); 2013 Apr; 120(4):665-71. PubMed ID: 23232665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
